Claims for Patent: 8,679,497

Summary for Patent: 8,679,497

Title:	Anti-ferroportin 1 monoclonal antibodies and uses thereof
Abstract:	Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo.
Inventor(s):	Leung; Donmienne Doen Mun (San Diego, CA), Luan; Peng (Livermore, CA), Manetta; Joseph Vincent (Indianapolis, IN), Tang; Ying (San Diego, CA), Witcher; Derrick Ryan (Fishers, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	13/465,462
Patent Claims:	1. A method of increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit comprising administering to a subject an effective amount of an anti-ferroportin 1 monoclonal antibody antibody comprising: a. the light chain and the heavy chain as shown in SEQ ID NO: 154 and SEQ ID NO: 152, respectively; b. the light chain and the heavy chain as shown in SEQ ID NO: 181 and SEQ ID NO: 179, respectively; or c. the light chain and the heavy chain as shown in SEQ ID NO: 158 and SEQ ID NO: 156, respectively. 2. A method of treating anemia, anemia of cancer, or anemia of cancer associated with elevated levels of hepcidin in a subject, comprising administering to the subject an effective amount of an anti-ferroportin 1 monoclonal antibody antibody comprising: a. the light chain and the heavy chain as shown in SEQ ID NO: 154 and SEQ ID NO: 152, respectively; b. the light chain and the heavy chain as shown in SEQ ID NO: 181 and SEQ ID NO: 179, respectively; or c. the light chain and the heavy chain as shown in SEQ ID NO: 158 and SEQ ID NO: 156, respectively. 3. The method of claim 1, wherein the monoclonal antibody comprises two light chain polypeptides and two heavy chain polypeptides, and wherein each of the light chain polypeptides have the amino acid sequence as shown in SEQ ID NO: 154 and each of the heavy chain polypeptides have the amino acid sequence as shown in SEQ ID NO: 152. 4. The method of claim 2, wherein the monoclonal antibody comprises two light chain polypeptides and two heavy chain polypeptides, and wherein each of the light chain polypeptides have the amino acid sequence as shown in SEQ ID NO: 154 and each of the heavy chain polypeptides have the amino acid sequence as shown in SEQ ID NO: 152. 5. The method of claim 1, further comprising administering to said human patient a therapeutic agent or therapeutic treatment conventionally employed to increase serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human. 6. The method of claim 5, wherein the therapeutic agent or therapeutic treatment is an erythropoiesis-stimulating agent (ESA). 7. The method of claim 6, wherein the ESA is selected from the group consisting of epoetin alfa, epoetin beta, erythropoietin, pegylated erythropoietin, carbamylated erythropoietin, hematide, and darbepoetin alfa. 8. The method of claim 2, further comprising administering to said human patient a therapeutic agent or therapeutic treatment conventionally employed to increase serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human. 9. The method of claim 8, wherein the therapeutic agent or therapeutic treatment is an ESA. 10. The method of claim 9, wherein the ESA is selected from the group consisting of epoetin alfa, epoetin beta, erythropoietin, pegylated erythropoietin, carbamylated erythropoietin, hematide, and darbepoetin alfa. 11. The method of claim 4, further comprising administering to said human patient a therapeutic agent or therapeutic treatment conventionally employed to increase serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human. 12. The method of claim 11, wherein the therapeutic agent or therapeutic treatment is an erythropoiesis-stimulating agent (ESA). 13. The method of claim 12, wherein the ESA is selected from the group consisting of epoetin alfa, epoetin beta, erythropoietin, pegylated erythropoietin, carbamylated erythropoietin, hematide, and darbepoetin alfa. 14. A polynucleotide comprising a nucleotide sequence encoding the light chain polypeptide as shown in SEQ ID NO: 154 or the heavy chain polypeptide as shown in SEQ ID NO: 152. 15. The polynucleotide according to claim 14 comprising a nucleotide sequence encoding the light chain polypeptide as shown in SEQ ID NO: 154 and the heavy chain polypeptide as shown in SEQ ID NO: 152. 16. A recombinant expression vector comprising the polynucleotide of claim 15. 17. A host cell which has been transformed by the expression vector of claim 16. 18. The host cell according to claim 17 wherein said cell is a Chinese hamster ovary (CHO), NS0 myeloma, COS, or SP2/0 cell. 19. A process for producing a monoclonal antibody comprising the steps of: (i) culturing the host cell of claim 17 under conditions suitable to allow expression of the monoclonal antibody; and (ii) recovering the expressed monoclonal antibody. 20. The process of claim 19, wherein said cell is a Chinese hamster ovary (CHO), NS0 myeloma, COS, or SP2/0 cell.

Details for Patent 8,679,497

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	06/01/1989		2028-12-05
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234			2028-12-05
Amgen, Inc.	PROCRIT	epoetin alfa	Injection	103234			2028-12-05